Compare QMCO & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QMCO | SCNX |
|---|---|---|
| Founded | 1980 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Other Pharmaceuticals |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.1M | 16.2M |
| IPO Year | 2025 | 2019 |
| Metric | QMCO | SCNX |
|---|---|---|
| Price | $18.20 | $3.23 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $27.33 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 49.6K |
| Earning Date | 11-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 64.34 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $372,827,000.00 | $3,831,778.00 |
| Revenue This Year | $20.02 | $743.36 |
| Revenue Next Year | $16.01 | $325.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 6.65 | ★ 30.72 |
| 52 Week Low | $4.19 | $2.64 |
| 52 Week High | $35.65 | $106.25 |
| Indicator | QMCO | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | 36.47 | 47.07 |
| Support Level | $16.74 | $2.64 |
| Resistance Level | $26.77 | $10.60 |
| Average True Range (ATR) | 1.79 | 0.32 |
| MACD | -0.34 | -0.02 |
| Stochastic Oscillator | 13.37 | 49.61 |
Quantum Corp is a United States-based company that delivers end-to-end data management solutions designed for unstructured data in the era of artificial intelligence (AI). It provides one of the comprehensive and cost-efficient solutions for the entire data lifecycle. The group provides solutions for video, images, audio, and other large files because this unstructured data represents. Its portfolio of products includes primary storage software and systems, secondary storage software and systems, as well as devices and media. The group operates in three geographic regions: Americas, Europe, the Middle East, and Africa (EMEA), and Asia Pacific (APAC).
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.